Macitentan tadalafil Fixed Dose Combination (FDC) in treatment-naive and prior monotherapy patients with Pulmonary Arterial Hypertension (PAH): insights from A DUE

Back

ESC Professional Premium Access

Macitentan tadalafil Fixed Dose Combination (FDC) in treatment-naive and prior monotherapy patients with Pulmonary Arterial Hypertension (PAH): insights from A DUE

Session: Current treatment of pulmonary hypertension: it is all about vasodilators

Topic: Pulmonary Hypertension

Speaker: Professor P. Jansa (Prague, CZ)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Pavel Jansa

First Faculty of Medicine and General Teaching Hospital, Prague (Czechia)

2 presentations

0 follower

7 more presentations in this session

Effect of a short course of parenteral treprostinil therapy on right heart structure and function in pulmonary arterial hypertension

Speaker: Doctor C. Vizza (Rome, IT)

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

Speaker: Doctor M. Pentikainen (Helsinki, FI)

The effect of sildenafil on maternal mortality in pulmonary arterial hypertension associated with congenital heart disease

Speaker: Doctor N. Nahdi (Yogyakarta, ID)

Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension

Speaker: Doctor G. martini (Bologna, IT)

Specific therapies of pulmonary hypertension and prognosis in COVID-19: 18-months analysis of BNP-PL national database.

Speaker: Doctor A. Mamzer (Lodz, PL)

Access the full session

Current treatment of pulmonary hypertension: it is all about vasodilators

Speakers: Professor P. Jansa, Doctor C. Vizza, Doctor M. Pentikainen, Doctor N. Nahdi, Doctor G. martini...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources